Seungbum Kang1, Young-Jung Roh. 1. Department of Ophthalmology and Visual Science, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
PURPOSE: To report the clinical experience of intravitreal ranibizumab administered as needed for the treatment of neovascular age-related macular degeneration (AMD). METHODS: We retrospectively reviewed the charts of 41 patients (41 eyes) with occult and minimally classic neovascular membrane in AMD. Patients received intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Forty-one eyes were retreated at the discretion of the treating physician on an as-needed basis after the first injection, instead of initially giving three monthly injections. The main outcomes measured were change in mean visual acuity and central retinal thickness, and the total number of injections received by patients during the 12 months. RESULTS: At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) visual acuity improved by 0.078 logMAR units (P = 0.046) and the mean central retinal thickness decreased by 85.7 μm (P < 0.001). Thirty of 41 eyes (73.2%) avoided any loss of vision, and 20 eyes (48.8 %) showed improved visual acuity. A mean of 4.07 injections were given over the 12 months. CONCLUSIONS: Ranibizumab administered on an as-needed basis may stabilize visual acuity in patients with neovascular AMD.
PURPOSE: To report the clinical experience of intravitreal ranibizumab administered as needed for the treatment of neovascular age-related macular degeneration (AMD). METHODS: We retrospectively reviewed the charts of 41 patients (41 eyes) with occult and minimally classic neovascular membrane in AMD. Patients received intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Forty-one eyes were retreated at the discretion of the treating physician on an as-needed basis after the first injection, instead of initially giving three monthly injections. The main outcomes measured were change in mean visual acuity and central retinal thickness, and the total number of injections received by patients during the 12 months. RESULTS: At 12 months, the mean logarithm of the minimum angle of resolution (logMAR) visual acuity improved by 0.078 logMAR units (P = 0.046) and the mean central retinal thickness decreased by 85.7 μm (P < 0.001). Thirty of 41 eyes (73.2%) avoided any loss of vision, and 20 eyes (48.8 %) showed improved visual acuity. A mean of 4.07 injections were given over the 12 months. CONCLUSIONS:Ranibizumab administered on an as-needed basis may stabilize visual acuity in patients with neovascular AMD.
Authors: F Giansanti; G Virgili; A Bini; E Rapizzi; G Giacomelli; M C Donati; T Verdina; U Menchini Journal: Eur J Ophthalmol Date: 2007 Mar-Apr Impact factor: 2.597
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2007-04 Impact factor: 5.258
Authors: Jeffrey S Heier; David S Boyer; Thomas A Ciulla; Philip J Ferrone; J Michael Jumper; Ronald C Gentile; Debbi Kotlovker; Carol Y Chung; Robert Y Kim Journal: Arch Ophthalmol Date: 2006-11
Authors: Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams Journal: Ophthalmology Date: 2006-02-14 Impact factor: 12.079
Authors: Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams Journal: Am J Ophthalmol Date: 2008-02 Impact factor: 5.258
Authors: Chui Ming Gemmy Cheung; Xiang Li; Ranjana Mathur; Shu Yen Lee; Choi Mun Chan; Ian Yeo; Boon Kwang Loh; Rachel Williams; Edmund Yick-Mun Wong; Doric Wong; Tien Yin Wong Journal: PLoS One Date: 2014-06-30 Impact factor: 3.240